https://vegfr-3inhibitor.com/w....orth-of-biopsy-withi
Consequently, we performed a meta-analysis of 8 scientific studies (n = 2243 patients) that evaluates the correlation between EZH2 mutations and overall success (OS) in clients with myeloid neoplasms. EZH2 mutations were associated with significantly worse OS (hazard ratio [HR] = 2.37, 95% private interval (CI), 1.48-3.79). In a word, EZH2 mutations indicate a poor prognosis for patients with myeloid neoplasms. © 2019 Chongqing Medical University. Production and hosting by
Like
Comment
Share
